AndrewJoeMD

Physician

Dr. Joe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
701 W 168th St
# Hhsc
New York, NY 10032
Phone+1 212-305-6916

Fax+1 212-305-6889

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1996 - 1999
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1991 - 1994
Icahn School of Medicine at Mount SinaiClass of 1991

PubMed

570 citations
T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Acro...
Patrick A. Ott, Yung-Jue Bang, Sarina Anne Piha-Paul, Albiruni Ryan Abdul Razak, Jaafar Bennouna
Journal of Clinical Oncology. 2019-02-01
1470 citations
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Razvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy
Science. 2018-10-12
295 citations
Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
Kerstin Trunzer, Anna C. Pavlick, Lynn M. Schuchter, Rene Gonzalez, Grant A. McArthur
Journal of Clinical Oncology. 2013-05-10

Journal Articles

Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based Immunotherapy
Jonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine

Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival RatesAugust 12th, 2024
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)April 17th, 2023
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory UpdateApril 14th, 2023
Join now to see all